Skip to main content
Top
Published in: Cancer Cell International 1/2021

Open Access 01-12-2021 | NSCLC | Correction

Correction to: Exosomal miR-126 blocks the development of non-small cell lung cancer through the inhibition of ITGA6

Authors: Mingjun Li, Qianqian Wang, Xiaofei Zhang, Ningning Yan, Xingya Li

Published in: Cancer Cell International | Issue 1/2021

Login to get access

Excerpt

Following the publication of the original article [1], the authors notified us that one of the primer sequences in the article was wrong:
  • Incorrect sequences: miR-126, F 5ʹ-TGTGGCTGTTAGGCATGG-3ʹ and R 5ʹ-AAGACTCAGGCCCAGGC-3ʹ
  • Corrected sequences: miR-126, F 5ʹ-CGCGTCGTACCGTGAGTAAT-3ʹ and R 5ʹ-AGTGCAGGGTCCGAGGTATT-3ʹ
Metadata
Title
Correction to: Exosomal miR-126 blocks the development of non-small cell lung cancer through the inhibition of ITGA6
Authors
Mingjun Li
Qianqian Wang
Xiaofei Zhang
Ningning Yan
Xingya Li
Publication date
01-12-2021
Publisher
BioMed Central
Keywords
NSCLC
NSCLC
Published in
Cancer Cell International / Issue 1/2021
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-021-01974-0

Other articles of this Issue 1/2021

Cancer Cell International 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine